Company Timeline

  • 2010

    PersImmune is founded

  • 2014

    PersImmune initiates blood and marrow collection protocol with UC San Diego for AML patients.

  • 2016

    MDS project started. IRB submission for collection protocol.

  • 2018

    PACTN Phase 1 Clinical Trial begins at UC San Diego. 3 patients enrolled; samples collected from 11 other individuals.

  • 2019

    Worldwide patents awarded for PACTN

    Cohort #1 of clinical trial is completed without toxicity. Cohort #2 approved to start.

    PACTN Clinical Trial expands to other UC medical centers

One Patient, One Tumor, One Therapy